The complete enrollment and zero discontinuations significantly de-risk the pivotal readout. Traders should monitor for: (1) any disclosure of baseline characteristics or blinded safety data, (2) enrollment updates on the European cohort, and (3) initiation of the rolling NDA in Q1 2027. The stock is likely to trade on these macro milestones until Q3 2027 data.
How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jun 30 $32.72entry
- T+1 · 5mo ago −0.03%α +0.10% · $32.71
- T+5 · 4mo ago −0.89%α −1.49% · $32.43
- T+20 · 4mo ago −10.42%α −9.39% · $29.31
- T+60 · 8w ago −20.20%α −23.77% · $26.11
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Stoke Therapeutics completed enrollment of 162 patients into the Phase 3 EMPEROR study of zorevunersen for Dravet syndrome, ahead of a Phase 3 data readout anticipated in Q3 2027 and a rolling NDA submission expected to begin in Q1 2027. This de-risks the pivotal trial timeline and sets up a potential U.S. launch by early 2028, though no efficacy or safety data have been released yet.
Key Facts
- Enrollment of 162 patients into the Phase 3 EMPEROR study of zorevunersen completed across U.S., U.K., and Japan.
- No patients have discontinued treatment in the study.
- Phase 3 data readout anticipated in Q3 2027; rolling NDA submission to FDA to begin Q1 2027 and complete H2 2027.
- Approximately 50 of 162 patients are through 28 weeks (primary endpoint of change in major motor seizure frequency).
- An additional cohort of ~30 patients in Europe is enrolling with last patient expected in August 2026.
- Stoke has a strategic collaboration with Biogen (Nasdaq: BIIB) for zorevunersen; Stoke retains U.S., Canada, Mexico rights.
- Zorevunersen has FDA Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Orphan Drug Designation.
Financial Impact
Enrollment completion and zero discontinuations reduce binary Phase 3 risk, supporting a potential U.S. launch by early 2028 for a first-in-class therapy targeting up to 38,000 patients in key markets (U.S. ~16,000). No financial terms disclosed.
Risk Factors
- Efficacy or safety failure at Phase 3 readout could wipe out value; the drug has not yet proven it works in a pivotal setting.
- Regulatory delays or need for additional trials beyond the current plan.
- Competition from other Dravet syndrome therapies, including ASMs and gene therapies in earlier development.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-289409 |
| Document: d924679dex991.htm | 0001193125-26-289409 |
| Document: 0001193125-26-289409-index-headers.html | 0001193125-26-289409 |
| Document: 0001193125-26-289409-index.html | 0001193125-26-289409 |
| Document: 0001193125-26-289409.txt | 0001193125-26-289409 |
Track record
18 reports on STOK
3 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +17.49% at T+60 after the Aug 3, 2026 report. 4 of 4 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $26.63 Now $26.63 −0.00% settles Feb 16
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $27.02 Now $26.63 −1.44% settles Feb 12
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $26.84 Now $26.63 −0.78% settles Feb 12
- Nov 13, 20263d ago SC 13G/A Neutral 3/10 Entry $26.12 Now $26.63 +1.95% settles Feb 12
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $26.07 Now $26.63 +2.15% settles Feb 3
- Oct 29, 202618d ago 8-K Neutral 5/10 Entry $26.29 Now $26.63 +1.29% settles Jan 28
- Oct 21, 202626d ago 144 Bearish 6/10 Entry $25.70 Now $26.63 −3.62% settles Jan 20
- Sep 30, 20266w ago SC 13G Neutral 4/10 Entry $26.01 Now $26.63 +2.38% settles Dec 28
- Sep 25, 20267w ago 8-K Neutral 2/10 Entry $25.50 Now $26.63 +4.43% settles Dec 22
- Aug 18, 202612w ago Insider Cluster Neutral 3/10 Entry $33.03 to $26.20 Now $26.63 −19.38% ▼ −20.68% −19.13% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers